🔗 Share this article

An underground market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Treatment Acquiring Traction Online

Retatrutide, which is still in clinical trials, is being promoted by social media influencers for its supposed fat-burning effects. Followers are encouraged to message these profiles privately for source information, while also obtaining discount codes.

Active Trade on Messaging Platforms

Additionally, a robust trade exists on Telegram, where groups with numerous of participants share “before and after” images, injection guides and claims of rapid British shipping. Vendors promote the substance there before directing customers to WhatsApp for transactions.

Understanding The Experimental Drug

This medication is an investigational injection developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Medical Professionals Voice Worries

Nevertheless, physicians and pharmacists have warned that the distribution of what remains an unlicensed drug in the UK is worrisome and could result in users administering products of unknown origin.

Some experts said the demand for retatrutide could be linked to the rising price of approved weight loss treatments such as Mounjaro.

Legal Status and Enforcement

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Several influencers attempt to circumvent the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and supply can still violate pharmaceutical, marketing, and consumer laws, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Content Elimination

Based on the social media company, the service has taken down problematic material and banned related keywords and search suggestions. The company stated it was dedicated to maintaining the platform secure and investing in enhancing compliance measures.

Online Trading Activities

Investigations also discovered groups with up to nine thousand participants marketing the experimental drug using Telegram's integrated discovery tool, which functions like a public directory. Typing “retatrutide” instantly displays channels with thousands of members, populated with images of weight loss, glowing testimonials and step-by-step guides for preparing or administering at home.

Within moments of entering one community, a vendor posted contact information, where most transactions take place. The seller provided an instruction manual and promised shipping within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None asked about body mass, health issues or previous experience.

Item Information and Pricing

Within these communities, messages show black plastic packages with Royal Mail stickers, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with sterile water, or ready-to-use pens typically sold at 160 pounds for 20 milligrams. When asked how long a injector should be used, vendors give contradictory responses ranging from a few weeks to “depends on your body”.

Service Oversight and Security Measures

A representative for Telegram said it actively moderated harmful content on its platform including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“People are administering materials they can’t verify. Even if the science behind this drug is valid, these online products may not include what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.

A medical professional of an online medical service linked the increase in interest to current price rises for approved weight-loss drugs such as Mounjaro. “With costs increasing, patients are using online platforms. But fake injections are extremely dangerous. You cannot know what’s contained or whether the environment they were produced in was clean,” she said.

Her team has already seen patients injured by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your well-being,” stated the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from the pharmaceutical company stated the substance was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this time no one can sell [it] for personal consumption,” they said, noting that any product “falsely representing itself as a Lilly investigational product not yet authorized … may expose users to potentially serious medical dangers”.